



## Recent Advances in Gastrointestinal Cancers: From Microbiota Modulation to New Therapeutic Approaches

Guest Editors:

**Dr. Serena Martinelli**

Department of Experimental and  
Clinical Medicine, University of  
Florence, 50139 Florence, Italy

**Dr. Elena Niccolai**

Department of Experimental and  
Clinical Medicine, University of  
Florence, Florence, Italy

Deadline for manuscript  
submissions:

**30 September 2024**

### Message from the Guest Editors

We are interested in:

- Modulation of the microbiota: role of the gut microbiome in influencing GI cancer development and response to treatment; manipulation of the microbiota through interventions such as probiotics, prebiotics, and fecal microbiota transplantation; and methods of modulating the microbiome to enhance response to immunotherapies, such as checkpoint inhibitors.
- Immunotherapy: efficacy of checkpoint inhibitors, such as pembrolizumab and nivolumab, in various GI malignancies and the exploration of CAR-T potential in GI cancers.
- Precision medicine: advances in molecular profiling and genomics, leading to the identification of specific biomarkers associated with GI cancers, and the development of liquid biopsy techniques for monitoring GI cancers.
- Targeted therapies: identify additional targeted therapies for specific subtypes of GI cancers in addition to HER2 therapies.
- Artificial intelligence in diagnostics: evaluation of machine learning algorithms to analyze medical images and to predict the prognosis and disease outcomes of GI cancers.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research

Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA

2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, St. Alban-Anlage 66  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)